CRISPR Therapeutics AG Key Executives
This section highlights CRISPR Therapeutics AG's key executives, including their titles and compensation details.
Find Contacts at CRISPR Therapeutics AG
( total contacts)
CRISPR Therapeutics AG Earnings
This section highlights CRISPR Therapeutics AG's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
$41.94
Stock Price
$3.60B
Market Cap
200.00K
Employees
Zug, None
Location
Financial Statements
Access annual & quarterly financial statements for CRISPR Therapeutics AG, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $35.00M | $371.21M | $436.00K | $913.08M | $543.00K |
| Cost of Revenue | $-2.31M | $130.25M | $110.25M | $17.95M | $269.41M |
| Gross Profit | $37.31M | $240.96M | $-109.81M | $895.13M | $-268.86M |
| Gross Profit Ratio | 106.61% | 64.90% | -25186.70% | 98.00% | -49514.55% |
| Research and Development Expenses | $320.65M | $387.33M | $461.64M | $438.63M | $266.95M |
| General and Administrative Expenses | $72.98M | $76.16M | $102.46M | $102.80M | $88.21M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $72.98M | $76.16M | $102.46M | $102.80M | $88.21M |
| Other Expenses | $110.25M | $-1.21M | $-762.00K | $-1.88M | $-176.00K |
| Operating Expenses | $503.88M | $462.29M | $563.35M | $539.55M | $354.98M |
| Cost and Expenses | $501.57M | $593.74M | $673.60M | $539.55M | $354.98M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $19.84M | $24.17M | $17.95M | $9.18M |
| EBITDA | $-466.57M | $-202.70M | $-648.99M | $391.48M | $-345.25M |
| EBITDA Ratio | -1333.05% | -54.61% | -154394.72% | 40.91% | -63582.14% |
| Operating Income | $-466.57M | $-222.54M | $-673.16M | $373.53M | $-354.44M |
| Operating Income Ratio | -1333.05% | -59.95% | -154394.72% | 40.91% | -65273.48% |
| Total Other Income Expenses Net | $103.90M | $71.82M | $22.66M | $6.00M | $6.38M |
| Income Before Tax | $-362.67M | $-150.72M | $-650.50M | $379.53M | $-348.06M |
| Income Before Tax Ratio | -1036.19% | -40.60% | -149197.25% | 41.57% | -64098.71% |
| Income Tax Expense | $3.59M | $2.89M | $-325.00K | $1.87M | $809.00K |
| Net Income | $-366.25M | $-153.61M | $-650.17M | $377.66M | $-348.87M |
| Net Income Ratio | -1046.43% | -41.38% | -149122.71% | 41.36% | -64247.70% |
| EPS | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 |
| EPS Diluted | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 |
| Weighted Average Shares Outstanding | 84.36M | 79.22M | 77.75M | 75.95M | 65.95M |
| Weighted Average Shares Outstanding Diluted | 84.36M | 79.22M | 77.75M | 80.39M | 65.95M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.00M | $602.00K | $517.00K | $504.00K | $200.00M | $- | $70.00M | $100.00M | $6.00K | $94.00K | $158.00K | $178.00K | $12.35M | $329.00K | $900.20M | $202.00K | $194.00K | $148.00K | $44.00K | $157.00K |
| Cost of Revenue | $- | $11.15M | $56.98M | $51.80M | $20.00M | $23.42M | $44.64M | $42.19M | $6.82M | $38.86M | $33.92M | $30.65M | $134.92M | $22.46M | $26.95M | $19.95M | $82.36M | $71.01M | $59.38M | $54.19M |
| Gross Profit | $35.00M | $-10.55M | $-56.46M | $-51.30M | $180.00M | $-23.42M | $25.36M | $57.81M | $-6.82M | $-38.77M | $-33.76M | $-30.47M | $-122.57M | $-22.14M | $873.26M | $-19.74M | $-82.17M | $-70.86M | $-59.34M | $-54.04M |
| Gross Profit Ratio | 100.00% | -1752.70% | -10920.50% | -10177.60% | 90.00% | 0.00% | 36.20% | 57.80% | -113616.70% | -41239.40% | -21369.60% | -17116.90% | -992.60% | -6728.00% | 97.00% | -9773.80% | -42356.19% | -47878.38% | -134854.55% | -34417.83% |
| Research and Development Expenses | $82.16M | $82.16M | $75.32M | $71.34M | $95.14M | $90.70M | $101.56M | $99.94M | $103.56M | $116.62M | $123.22M | $118.25M | $134.47M | $105.32M | $108.28M | $90.56M | $82.36M | $71.01M | $59.38M | $54.19M |
| General and Administrative Expenses | $18.12M | $17.42M | $19.48M | $17.95M | $16.48M | $18.29M | $19.03M | $22.36M | $21.17M | $27.00M | $26.27M | $28.02M | $24.13M | $24.35M | $29.81M | $24.52M | $25.77M | $21.54M | $21.35M | $19.55M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.12M | $17.42M | $19.48M | $17.95M | $16.48M | $18.29M | $19.03M | $22.36M | $21.17M | $27.00M | $26.27M | $28.02M | $24.13M | $24.35M | $29.81M | $24.52M | $25.77M | $21.54M | $21.35M | $19.55M |
| Other Expenses | $-691.00K | $- | $26.14M | $24.72M | $20.00M | $20.67M | $18.41M | $12.74M | $11.49M | $7.26M | $3.54M | $-762.00K | $2.20M | $1.10M | $750.00K | $1.96M | $575.00K | $160.00K | $1.41M | $4.23M |
| Operating Expenses | $99.59M | $99.58M | $94.80M | $89.29M | $110.42M | $108.99M | $120.59M | $122.30M | $124.72M | $143.62M | $149.50M | $145.50M | $158.05M | $129.18M | $137.58M | $114.75M | $107.95M | $92.55M | $80.73M | $73.74M |
| Cost and Expenses | $99.59M | $110.73M | $151.78M | $141.09M | $130.42M | $132.41M | $165.22M | $164.49M | $131.55M | $182.48M | $183.42M | $176.15M | $158.05M | $129.18M | $137.58M | $114.75M | $107.95M | $92.55M | $80.73M | $73.74M |
| Interest Income | $- | $- | $- | $- | $- | $20.67M | $18.41M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $4.84M | $4.80M | $4.84M | $4.83M | $4.90M | $4.92M | $4.96M | $5.05M | $5.85M | $5.02M | $7.27M | $6.04M | $6.26M | $5.32M | $3.65M | $2.71M | $2.57M | $2.33M | $2.19M | $2.09M |
| EBITDA | $-59.75M | $-105.39M | $-146.41M | $-135.75M | $74.48M | $-127.49M | $-90.26M | $-59.44M | $-125.69M | $-177.37M | $-175.99M | $-169.93M | $-139.44M | $-123.53M | $766.27M | $-111.83M | $-105.19M | $-90.06M | $-78.50M | $-71.50M |
| EBITDA Ratio | -170.70% | -17506.81% | -28320.12% | -26935.32% | 37.24% | 0.00% | -128.95% | -64.49% | -2192350.00% | -188691.49% | -115987.34% | -95467.98% | -1179.93% | -37545.59% | 85.12% | -55360.40% | -54224.23% | -62431.76% | -183384.09% | -46870.06% |
| Operating Income | $-64.59M | $-110.13M | $-151.26M | $-140.59M | $69.58M | $-132.41M | $-95.22M | $-64.49M | $-131.54M | $-182.39M | $-183.26M | $-175.97M | $-145.70M | $-128.85M | $762.62M | $-114.54M | $-107.76M | $-92.40M | $-80.69M | $-73.59M |
| Operating Income Ratio | -184.54% | -18294.02% | -29257.25% | -27894.25% | 34.79% | 0.00% | -136.03% | -64.49% | -2192350.00% | -194029.79% | -115987.34% | -98860.67% | -1179.93% | -39163.83% | 84.72% | -56704.46% | -55546.91% | -62431.76% | -183384.09% | -46870.06% |
| Total Other Income Expenses Net | $27.98M | $25.06M | $26.14M | $24.72M | $20.00M | $20.67M | $18.41M | $12.74M | $11.49M | $7.26M | $3.54M | $363.00K | $2.20M | $1.10M | $750.00K | $1.96M | $575.00K | $160.00K | $1.41M | $4.23M |
| Income Before Tax | $-36.61M | $-85.07M | $-125.12M | $-115.87M | $89.58M | $-111.74M | $-76.82M | $-51.74M | $-120.05M | $-175.12M | $-179.72M | $-175.61M | $-143.50M | $-127.75M | $763.37M | $-112.59M | $-107.19M | $-92.24M | $-79.28M | $-69.35M |
| Income Before Tax Ratio | -104.60% | -14130.56% | -24201.35% | -22989.48% | 44.79% | 0.00% | -109.74% | -51.74% | -2000850.00% | -186302.13% | -113744.30% | -98656.74% | -1162.14% | -38829.18% | 84.80% | -55736.63% | -55250.52% | -62323.65% | -180175.00% | -44174.52% |
| Income Tax Expense | $700.00K | $876.00K | $1.29M | $724.00K | $233.00K | $-412.00K | $923.00K | $1.32M | $-9.48M | $-575.00K | $6.12M | $3.61M | $-2.25M | $-595.00K | $4.14M | $575.00K | $-147.00K | $200.00K | $379.00K | $377.00K |
| Net Income | $-37.31M | $-85.94M | $-126.41M | $-116.59M | $89.35M | $-112.15M | $-77.74M | $-53.06M | $-110.58M | $-174.55M | $-185.83M | $-179.22M | $-141.25M | $-127.15M | $759.23M | $-113.16M | $-107.04M | $-92.44M | $-79.66M | $-69.73M |
| Net Income Ratio | -106.60% | -14276.08% | -24450.29% | -23133.13% | 44.67% | 0.00% | -111.06% | -53.06% | -1842916.67% | -185690.43% | -117616.46% | -100683.71% | -1143.89% | -38648.33% | 84.34% | -56021.29% | -55174.74% | -62458.78% | -181036.36% | -44414.65% |
| EPS | $-0.44 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.41 | $-2.24 | $-2.40 | $-2.32 | $-1.84 | $-1.67 | $10.01 | $-1.51 | $-1.53 | $-1.32 | $-1.30 | $-1.15 |
| EPS Diluted | $-0.44 | $-1.01 | $-1.49 | $-1.43 | $1.10 | $-1.41 | $-0.98 | $-0.67 | $-1.41 | $-2.24 | $-2.40 | $-2.32 | $-1.84 | $-1.67 | $9.44 | $-1.51 | $-1.53 | $-1.32 | $-1.30 | $-1.15 |
| Weighted Average Shares Outstanding | 84.36M | 85.23M | 84.92M | 81.79M | 79.69M | 79.41M | 79.09M | 78.68M | 78.34M | 77.92M | 77.43M | 77.10M | 76.65M | 76.14M | 75.83M | 74.94M | 70.14M | 70.03M | 61.27M | 60.64M |
| Weighted Average Shares Outstanding Diluted | 84.36M | 85.23M | 84.92M | 81.79M | 81.32M | 79.41M | 79.09M | 78.68M | 78.34M | 78.02M | 77.51M | 77.10M | 76.65M | 76.29M | 80.45M | 75.01M | 70.14M | 70.14M | 61.42M | 60.85M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B |
| Short Term Investments | $1.61B | $1.30B | $1.60B | $1.46B | $521.71M |
| Cash and Short Term Investments | $1.90B | $1.69B | $1.82B | $2.38B | $1.69B |
| Net Receivables | $25.00M | $200.00M | $- | $305.00K | $144.00K |
| Inventory | $- | $- | $-11.20M | $- | $- |
| Other Current Assets | $8.31M | $14.39M | $37.71M | $29.68M | $15.44M |
| Total Current Assets | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B |
| Property Plant Equipment Net | $277.55M | $305.94M | $320.56M | $312.04M | $93.03M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $16.00K | $71.00K | $125.00K | $180.00K |
| Goodwill and Intangible Assets | $- | $16.00K | $71.00K | $125.00K | $180.00K |
| Long Term Investments | $- | $1.97M | $53.13M | $16.91M | $16.85M |
| Tax Assets | $- | $- | $- | $-16.91M | $-16.85M |
| Other Non-Current Assets | $27.35M | $13.57M | $16.27M | $22.20M | $18.14M |
| Total Non-Current Assets | $304.90M | $321.49M | $390.03M | $334.36M | $111.35M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B |
| Account Payables | $14.71M | $38.15M | $27.43M | $14.82M | $9.09M |
| Short Term Debt | $17.29M | $43.61M | $31.68M | $24.32M | $22.72M |
| Tax Payables | $451.00K | $438.00K | $135.00K | $724.00K | $10.47M |
| Deferred Revenue | $3.85M | $4.11M | $12.32M | $1.01M | $2.34M |
| Other Current Liabilities | $51.49M | $50.48M | $61.86M | $79.02M | $49.63M |
| Total Current Liabilities | $87.78M | $108.79M | $121.11M | $119.88M | $94.26M |
| Long Term Debt | $206.41M | $223.01M | $228.18M | $212.87M | $50.07M |
| Deferred Revenue Non-Current | $- | $14.01M | $12.32M | $12.32M | $11.78M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $15.77M | $958.00K | $5.97M | $7.34M | $7.63M |
| Total Non-Current Liabilities | $222.17M | $237.98M | $246.47M | $232.53M | $69.47M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $309.95M | $346.77M | $367.58M | $352.42M | $163.73M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.70M | $2.50M | $2.44M | $2.39M | $2.28M |
| Retained Earnings | $-1.37B | $-999.70M | $-846.09M | $-195.91M | $-573.58M |
| Accumulated Other Comprehensive Income Loss | $1.84M | $1.91M | $-15.65M | $-5.07M | $-83.00K |
| Other Total Stockholders Equity | $3.29B | $2.88B | $2.73B | $2.60B | $2.24B |
| Total Stockholders Equity | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B |
| Total Equity | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B |
| Total Liabilities and Stockholders Equity | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B |
| Total Investments | $1.61B | $1.31B | $1.66B | $1.46B | $521.71M |
| Total Debt | $223.69M | $238.63M | $244.02M | $225.03M | $61.43M |
| Net Debt | $-74.56M | $-150.84M | $32.14M | $-698.00M | $-1.11B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $298.26M | $225.67M | $484.47M | $707.43M | $389.48M | $527.76M | $444.80M | $344.41M | $211.88M | $494.15M | $496.89M | $683.91M | $923.03M | $1.01B | $1.65B | $1.13B | $1.17B | $1.04B | $945.07M | $889.71M |
| Short Term Investments | $1.61B | $1.71B | $1.52B | $1.40B | $1.30B | $1.21B | $1.32B | $1.54B | $1.60B | $1.40B | $1.57B | $1.54B | $1.46B | $1.47B | $942.80M | $680.14M | $521.71M | $324.57M | $- | $- |
| Cash and Short Term Investments | $1.90B | $1.94B | $2.00B | $2.11B | $1.69B | $1.74B | $1.77B | $344.41M | $1.82B | $1.90B | $2.07B | $2.22B | $2.38B | $2.48B | $2.59B | $1.81B | $1.69B | $1.37B | $945.07M | $889.71M |
| Net Receivables | $25.00M | $- | $- | $- | $200.00M | $- | $70.00M | $- | $- | $49.00K | $66.00K | $143.00K | $305.00K | $152.00K | $150.00K | $150.00K | $144.00K | $110.00K | $33.00K | $25.12M |
| Inventory | $- | $- | $- | $- | $- | $- | $1 | $- | $-11.20M | $1 | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- |
| Other Current Assets | $8.31M | $8.25M | $8.79M | $11.50M | $14.39M | $20.76M | $21.47M | $24.80M | $37.71M | $69.30M | $79.20M | $73.62M | $29.68M | $82.85M | $62.69M | $52.01M | $15.44M | $49.68M | $41.03M | $28.91M |
| Total Current Assets | $1.94B | $1.94B | $2.01B | $2.12B | $1.91B | $1.76B | $1.86B | $1.91B | $1.85B | $1.93B | $2.11B | $2.26B | $2.42B | $2.52B | $2.62B | $1.83B | $1.72B | $1.39B | $965.62M | $929.28M |
| Property Plant Equipment Net | $277.55M | $284.83M | $291.57M | $298.51M | $305.94M | $312.34M | $318.52M | $315.54M | $320.56M | $327.62M | $331.93M | $328.99M | $312.04M | $281.01M | $254.79M | $102.04M | $93.03M | $76.38M | $73.74M | $72.09M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $2.00K | $16.00K | $30.00K | $43.00K | $57.00K | $71.00K | $84.00K | $98.00K | $112.00K | $125.00K | $139.00K | $153.00K | $167.00K | $180.00K | $194.00K | $208.00K | $221.00K |
| Goodwill and Intangible Assets | $- | $- | $- | $2.00K | $16.00K | $30.00K | $43.00K | $57.00K | $71.00K | $84.00K | $98.00K | $112.00K | $125.00K | $139.00K | $153.00K | $167.00K | $180.00K | $194.00K | $208.00K | $221.00K |
| Long Term Investments | $- | $- | $22.74M | $11.52M | $1.97M | $11.83M | $4.90M | $6.32M | $53.13M | $77.15M | $8.39M | $12.12M | $16.91M | $16.85M | $18.07M | $16.84M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $-11.52M | $- | $-11.83M | $- | $- | $- | $- | $- | $-12.12M | $-16.91M | $-16.85M | $-18.07M | $-16.84M | $- | $- | $- | $- |
| Other Non-Current Assets | $27.35M | $27.41M | $15.14M | $20.88M | $13.57M | $13.88M | $13.97M | $14.48M | $16.27M | $15.80M | $15.88M | $4.33M | $5.29M | $4.79M | $5.56M | $6.50M | $18.14M | $17.51M | $6.96M | $5.70M |
| Total Non-Current Assets | $304.90M | $312.24M | $329.45M | $319.39M | $321.49M | $326.24M | $337.44M | $336.40M | $390.03M | $420.65M | $356.31M | $345.56M | $334.36M | $302.79M | $278.58M | $125.55M | $111.35M | $94.08M | $80.91M | $78.02M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $2.24B | $2.26B | $2.34B | $2.44B | $2.23B | $2.09B | $2.20B | $2.24B | $2.24B | $2.35B | $2.46B | $2.61B | $2.75B | $2.82B | $2.90B | $1.96B | $1.83B | $1.49B | $1.05B | $1.01B |
| Account Payables | $14.71M | $15.58M | $9.45M | $16.46M | $38.15M | $26.15M | $27.59M | $45.15M | $27.43M | $27.84M | $25.24M | $27.11M | $14.82M | $10.17M | $10.14M | $13.07M | $9.09M | $19.02M | $13.22M | $11.28M |
| Short Term Debt | $17.29M | $33.77M | $32.90M | $15.99M | $31.25M | $30.00M | $29.67M | $15.72M | $15.84M | $22.52M | $8.27M | $22.15M | $12.16M | $25.28M | $31.75M | $24.13M | $22.72M | $21.28M | $19.81M | $18.01M |
| Tax Payables | $451.00K | $838.00K | $454.00K | $1.21M | $438.00K | $176.00K | $558.00K | $273.00K | $135.00K | $4.27M | $3.95M | $2.61M | $724.00K | $3.27M | $4.46M | $3.36M | $10.47M | $6.35M | $1.51M | $284.00K |
| Deferred Revenue | $3.85M | $4.48M | $4.76M | $4.07M | $4.11M | $3.50M | $12.32M | $12.32M | $12.32M | $12.32M | $12.32M | $12.32M | $1.01M | $1.56M | $2.07M | $1.80M | $2.34M | $610.00K | $759.00K | $803.00K |
| Other Current Liabilities | $51.49M | $35.15M | $80.26M | $81.26M | $34.85M | $86.91M | $75.03M | $85.65M | $77.70M | $96.24M | $82.49M | $61.83M | $91.17M | $55.93M | $51.49M | $40.73M | $49.63M | $36.89M | $39.21M | $24.71M |
| Total Current Liabilities | $87.78M | $89.81M | $127.82M | $118.99M | $108.79M | $111.23M | $132.84M | $146.79M | $121.11M | $150.87M | $119.96M | $113.70M | $119.88M | $96.21M | $99.92M | $83.09M | $94.26M | $84.15M | $74.50M | $55.09M |
| Long Term Debt | $206.41M | $210.66M | $214.85M | $218.94M | $223.01M | $226.59M | $230.34M | $224.55M | $228.18M | $230.90M | $234.16M | $227.90M | $212.87M | $192.73M | $175.33M | $49.41M | $50.07M | $38.57M | $40.32M | $42.39M |
| Deferred Revenue Non-Current | $12.32M | $12.32M | $12.58M | $13.54M | $14.01M | $15.82M | $12.32M | $12.32M | $12.32M | $12.32M | $12.32M | $12.32M | $12.32M | $11.78M | $11.78M | $11.78M | $11.78M | $11.78M | $11.78M | $11.78M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.44M | $3.68M | $3.65M | $3.62M | $958.00K | $5.39M | $5.48M | $5.80M | $5.97M | $5.31M | $6.09M | $7.33M | $7.34M | $8.09M | $8.70M | $8.14M | $7.63M | $7.22M | $9.26M | $11.95M |
| Total Non-Current Liabilities | $222.17M | $226.66M | $231.08M | $236.09M | $237.98M | $247.80M | $248.15M | $242.67M | $246.47M | $248.53M | $252.57M | $247.56M | $232.53M | $212.60M | $195.80M | $69.32M | $69.47M | $57.57M | $61.36M | $66.12M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $309.95M | $316.47M | $358.90M | $355.08M | $346.77M | $359.04M | $380.99M | $389.47M | $367.58M | $399.40M | $372.53M | $361.26M | $352.42M | $308.80M | $295.72M | $152.41M | $163.73M | $141.72M | $135.86M | $121.20M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.70M | $2.68M | $2.67M | $2.66M | $2.50M | $2.48M | $2.47M | $2.45M | $2.44M | $2.43M | $2.42M | $2.41M | $2.39M | $2.37M | $2.35M | $2.34M | $2.28M | $2.16M | $1.90M | $1.85M |
| Retained Earnings | $-1.37B | $-1.33B | $-1.24B | $-1.12B | $-999.70M | $-1.09B | $-976.89M | $-899.15M | $-846.09M | $-735.51M | $-560.97M | $-375.13M | $-195.91M | $-54.67M | $72.49M | $-686.74M | $-573.58M | $-466.54M | $-374.10M | $-294.44M |
| Accumulated Other Comprehensive Income Loss | $1.84M | $10.56M | $-2.88M | $-1.55M | $1.91M | $-6.80M | $-8.91M | $-9.39M | $-15.65M | $-22.26M | $-20.34M | $-16.89M | $-5.07M | $-770.00K | $-629.00K | $-461.00K | $-83.00K | $-134.00K | $-21.00K | $-18.00K |
| Other Total Stockholders Equity | $3.29B | $3.26B | $3.22B | $3.20B | $2.88B | $2.82B | $2.80B | $2.76B | $2.73B | $2.71B | $2.67B | $2.63B | $2.60B | $2.57B | $2.53B | $2.49B | $2.24B | $1.81B | $1.28B | $1.18B |
| Total Stockholders Equity | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | $2.09B | $2.24B | $2.40B | $2.51B | $2.60B | $1.81B | $1.66B | $1.34B | $910.67M | $886.10M |
| Total Equity | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | $2.09B | $2.24B | $2.40B | $2.51B | $2.60B | $1.81B | $1.66B | $1.34B | $910.67M | $886.10M |
| Total Liabilities and Stockholders Equity | $2.24B | $2.26B | $2.34B | $2.44B | $2.23B | $2.09B | $2.20B | $2.24B | $2.24B | $2.35B | $2.46B | $2.61B | $2.75B | $2.82B | $2.90B | $1.96B | $1.83B | $1.49B | $1.05B | $1.01B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.24B | $2.26B | $2.34B | $2.44B | $2.23B | $2.09B | $2.20B | $2.24B | $2.24B | $2.35B | $2.46B | $2.61B | $2.75B | $2.82B | $2.90B | $1.96B | $1.83B | $1.49B | $1.05B | $1.01B |
| Total Investments | $1.61B | $1.71B | $1.54B | $1.41B | $1.31B | $1.21B | $1.33B | $1.55B | $1.66B | $1.48B | $1.58B | $1.54B | $1.46B | $1.47B | $942.80M | $680.14M | $521.71M | $324.57M | $- | $- |
| Total Debt | $223.69M | $227.54M | $231.30M | $234.93M | $238.63M | $241.59M | $245.18M | $240.27M | $244.02M | $242.16M | $242.43M | $238.98M | $225.03M | $205.38M | $191.20M | $61.47M | $61.43M | $49.21M | $50.22M | $51.40M |
| Net Debt | $-74.56M | $1.88M | $-253.17M | $-472.50M | $-150.84M | $-286.18M | $-199.62M | $-104.14M | $32.14M | $-252.00M | $-254.47M | $-444.93M | $-698.00M | $-806.17M | $-1.46B | $-1.06B | $-1.11B | $-992.21M | $-894.85M | $-838.32M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-366.25M | $-153.61M | $-650.17M | $377.66M | $-348.87M |
| Depreciation and Amortization | $19.26M | $19.84M | $24.17M | $17.95M | $9.18M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $86.57M | $81.03M | $97.95M | $102.39M | $66.02M |
| Change in Working Capital | $156.27M | $-193.59M | $19.84M | $26.86M | $33.44M |
| Accounts Receivables | $175.00M | $-200.00M | $305.00K | $-161.00K | $-45.00K |
| Inventory | $- | $23.33M | $- | $-37.51M | $-25.75M |
| Accounts Payables | $- | $-20.25M | $5.16M | $37.51M | $25.75M |
| Other Working Capital | $-18.73M | $3.33M | $14.38M | $27.02M | $33.48M |
| Other Non Cash Items | $-38.62M | $-14.04M | $12.47M | $14.11M | $1.86M |
| Net Cash Provided by Operating Activities | $-142.77M | $-260.38M | $-495.74M | $538.97M | $-238.37M |
| Investments in Property Plant and Equipment | $-1.90M | $-9.47M | $-37.19M | $-81.70M | $-18.36M |
| Acquisitions Net | $- | $- | $221.47M | $953.73M | $522.81M |
| Purchases of Investments | $-1.46B | $-1.07B | $-1.42B | $-1.51B | $-594.00M |
| Sales Maturities of Investments | $1.21B | $1.45B | $1.20B | $555.60M | $71.19M |
| Other Investing Activities | $-23.18M | $-2.50M | $-221.47M | $-953.73M | $-522.81M |
| Net Cash Used for Investing Activities | $-280.48M | $374.65M | $-258.65M | $-1.04B | $-541.17M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $300.69M | $32.72M | $970.00K | $213.27M | $982.29M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $31.29M | $29.94M | $37.62M | $37.68M | $33.86M |
| Net Cash Used Provided by Financing Activities | $331.98M | $62.66M | $38.59M | $250.94M | $1.02B |
| Effect of Forex Changes on Cash | $-21.00K | $73.00K | $-80.00K | $-11.00K | $40.00K |
| Net Change in Cash | $-91.29M | $177.01M | $-715.88M | $-245.52M | $236.66M |
| Cash at End of Period | $309.78M | $401.07M | $224.06M | $939.94M | $1.19B |
| Cash at Beginning of Period | $401.07M | $224.06M | $939.94M | $1.19B | $948.81M |
| Operating Cash Flow | $-142.77M | $-260.38M | $-495.74M | $538.97M | $-238.37M |
| Capital Expenditure | $-1.90M | $-11.97M | $-37.19M | $-81.70M | $-18.36M |
| Free Cash Flow | $-144.68M | $-272.35M | $-532.93M | $457.27M | $-256.72M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-37.31M | $-85.94M | $-126.41M | $-116.59M | $89.35M | $-112.15M | $-77.74M | $-53.06M | $-110.58M | $-174.55M | $-185.83M | $-179.22M | $-141.25M | $-127.15M | $759.23M | $-113.16M | $-107.04M | $-92.44M | $-79.66M | $-69.73M |
| Depreciation and Amortization | $4.84M | $4.74M | $4.84M | $4.83M | $4.90M | $4.92M | $4.96M | $5.05M | $5.85M | $5.02M | $7.27M | $6.04M | $6.26M | $5.32M | $3.65M | $2.71M | $2.57M | $2.33M | $2.19M | $2.09M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $21.95M | $21.54M | $23.67M | $19.41M | $18.42M | $19.97M | $21.77M | $20.88M | $22.80M | $24.55M | $24.85M | $25.75M | $25.77M | $26.20M | $28.33M | $22.09M | $18.93M | $17.24M | $15.70M | $14.15M |
| Change in Working Capital | $-24.35M | $-40.36M | $10.49M | $210.49M | $-203.97M | $52.56M | $-79.08M | $36.91M | $-31.62M | $37.19M | $8.19M | $6.09M | $18.49M | $9.30M | $13.44M | $-14.37M | $3.45M | $-2.93M | $32.49M | $424.00K |
| Accounts Receivables | $-25.00M | $- | $- | $200.00M | $-200.00M | $70.00M | $-70.00M | $- | $49.00K | $17.00K | $77.00K | $162.00K | $-153.00K | $-2.00K | $- | $-6.00K | $-34.00K | $-77.00K | $25.08M | $-25.02M |
| Inventory | $- | $- | $- | $- | $9.19M | $24.69M | $11.58M | $- | $- | $-27.96M | $- | $1.62M | $-8.69M | $- | $- | $-8.83M | $-23.80M | $- | $- | $28.06M |
| Accounts Payables | $- | $-38.16M | $9.28M | $9.44M | $-9.19M | $-24.69M | $-11.58M | $25.21M | $-3.14M | $27.96M | $8.30M | $-1.62M | $37.51M | $1.31M | $19.20M | $-5.77M | $25.75M | $- | $- | $-2.50M |
| Other Working Capital | $646.00K | $-2.20M | $1.21M | $1.05M | $-3.97M | $-17.44M | $-9.08M | $11.69M | $-28.53M | $37.17M | $-195.00K | $5.93M | $-10.18M | $9.30M | $13.44M | $239.00K | $1.54M | $-2.85M | $7.41M | $-120.00K |
| Other Non Cash Items | $-15.15M | $-6.90M | $15.90M | $-188.76M | $-4.77M | $-5.16M | $-3.15M | $-969.00K | $219.00K | $2.58M | $3.57M | $6.10M | $4.69M | $5.00M | $2.35M | $2.06M | $878.00K | $90.00K | $-1.00K | $890.00K |
| Net Cash Provided by Operating Activities | $-50.03M | $-106.91M | $-95.58M | $109.75M | $-96.07M | $-39.86M | $-133.25M | $8.80M | $-113.33M | $-105.22M | $-141.96M | $-135.24M | $-86.04M | $-81.33M | $807.00M | $-100.66M | $-81.21M | $-75.70M | $-29.28M | $-52.17M |
| Investments in Property Plant and Equipment | $-254.00K | $-219.00K | $-707.00K | $-721.00K | $-738.00K | $-2.12M | $-3.56M | $-3.06M | $-6.19M | $-6.02M | $-9.63M | $-15.35M | $-9.18M | $-37.05M | $-28.45M | $-7.02M | $-6.24M | $-5.52M | $-3.60M | $-2.99M |
| Acquisitions Net | $- | $- | $- | $- | $80.72M | $- | $- | $-120.89M | $169.34M | $-93.48M | $46.44M | $- | $- | $- | $- | $- | $-324.81M | $- | $- | $- |
| Purchases of Investments | $-266.92M | $-388.68M | $-475.98M | $-334.42M | $-368.15M | $-245.40M | $-186.74M | $-265.63M | $-494.40M | $-326.27M | $-274.00M | $-323.14M | $-122.54M | $-670.80M | $-392.01M | $-323.98M | $-268.68M | $-325.32M | $- | $- |
| Sales Maturities of Investments | $373.00M | $247.68M | $349.78M | $237.34M | $287.43M | $369.87M | $408.71M | $386.51M | $325.06M | $419.75M | $227.55M | $223.97M | $123.01M | $142.67M | $126.82M | $163.10M | $70.68M | $509.00K | $- | $- |
| Other Investing Activities | $- | $-20.39M | $-126.20M | $-7.50M | $-80.72M | $-1.00M | $-1.50M | $120.89M | $-169.34M | $93.48M | $-46.44M | $-99.17M | $467.00K | $-528.13M | $-265.19M | $-160.87M | $324.81M | $-324.81M | $- | $- |
| Net Cash Used for Investing Activities | $105.83M | $-161.60M | $-126.91M | $-97.80M | $-81.45M | $121.35M | $216.92M | $117.83M | $-175.53M | $87.46M | $-56.07M | $-114.52M | $-8.72M | $-565.18M | $-293.64M | $-167.90M | $-204.24M | $-330.33M | $-3.60M | $-2.99M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.77M | $11.40M | $- | $- | $6.48M | $1.13M |
| Common Stock Issued | $14.96M | $6.00M | $-1.01M | $280.75M | $32.72M | $1.56M | $16.77M | $5.40M | $2.48M | $970.00K | $10.35M | $10.65M | $6.30M | $10.21M | $-1.32M | $214.59M | $400.06M | $499.20M | $83.02M | $- |
| Common Stock Repurchased | $- | $466.00K | $-466.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.92M | $3.64M | $546.00K | $25.19M | $6.22M | $1.56M | $16.77M | $5.40M | $2.48M | $14.14M | $10.35M | $10.65M | $6.30M | $10.21M | $-1.32M | $- | $12.56M | $13.68M | $- | $- |
| Net Cash Used Provided by Financing Activities | $16.88M | $9.64M | $-466.00K | $305.93M | $38.94M | $1.56M | $16.77M | $5.40M | $2.48M | $15.11M | $10.35M | $10.65M | $6.30M | $10.21M | $8.44M | $225.99M | $412.63M | $512.89M | $89.50M | $1.13M |
| Effect of Forex Changes on Cash | $-87.00K | $75.00K | $2.00K | $-11.00K | $61.00K | $-48.00K | $28.00K | $32.00K | $115.00K | $-100.00K | $-68.00K | $-27.00K | $3.00K | $-24.00K | $5.00K | $5.00K | $35.00K | $33.00K | $-3.00K | $-25.00K |
| Net Change in Cash | $72.59M | $-247.28M | $-222.96M | $317.95M | $-138.53M | $83.00M | $100.47M | $132.06M | $-286.27M | $-2.74M | $-187.74M | $-239.13M | $-88.45M | $-636.32M | $521.81M | $-42.56M | $127.21M | $106.89M | $56.62M | $-54.06M |
| Cash at End of Period | $309.78M | $237.19M | $484.47M | $707.43M | $401.07M | $539.60M | $456.60M | $356.12M | $224.06M | $510.33M | $513.07M | $700.81M | $939.94M | $1.03B | $1.66B | $1.14B | $1.19B | $1.06B | $951.37M | $894.75M |
| Cash at Beginning of Period | $237.19M | $484.47M | $707.43M | $389.48M | $539.60M | $456.60M | $356.12M | $224.06M | $510.33M | $513.07M | $700.81M | $939.94M | $1.03B | $1.66B | $1.14B | $1.19B | $1.06B | $951.37M | $894.75M | $948.81M |
| Operating Cash Flow | $-50.03M | $-106.91M | $-95.58M | $109.75M | $-96.07M | $-39.86M | $-133.25M | $8.80M | $-113.33M | $-105.22M | $-141.96M | $-135.24M | $-86.04M | $-81.33M | $807.00M | $-100.66M | $-81.21M | $-75.70M | $-29.28M | $-52.17M |
| Capital Expenditure | $-254.00K | $-219.00K | $-707.00K | $-721.00K | $-738.00K | $-2.12M | $-3.56M | $-3.06M | $-6.19M | $-6.02M | $-9.63M | $-15.35M | $-9.18M | $-37.05M | $-28.45M | $-7.02M | $-6.24M | $-5.52M | $-3.60M | $-2.99M |
| Free Cash Flow | $-50.28M | $-107.13M | $-96.29M | $109.03M | $-96.81M | $-41.97M | $-136.80M | $5.74M | $-119.52M | $-111.23M | $-151.59M | $-150.59M | $-95.22M | $-118.38M | $778.55M | $-107.69M | $-87.45M | $-81.22M | $-32.88M | $-55.17M |
CRISPR Therapeutics AG Dividends
Explore CRISPR Therapeutics AG's dividend history, including dividend yield, payout ratio, and historical payments.
CRISPR Therapeutics AG News
Read the latest news about CRISPR Therapeutics AG, including recent articles, headlines, and updates.
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Welcome again to TD Cowen's 45th Annual Healthcare Conference, our first day.
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Explore the exciting world of CRISPR Therapeutics (CRSP 0.69%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth.
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare company's latest quarterly earnings report, which was published after market hours Tuesday.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- -CRISPR Therapeutics and Nkure Therapeutics Private Limited establish global strategic partnership to co-develop and co-commercialize CTX112 in India- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and LPA, respectively; updates expected in the first half of 2025- -Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2024- ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. "With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics is poised to make meaningful strides in transforming the landscape of medicine.
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CRSP.